RCT OF PREVENTION OF ACCELERATED ATHEROSCLEROSIS IN SLE

描述（取自应用程序）： 系统性红斑狼疮（SLE）影响超过20万美国人。已经 已知超过20年，SLE患者的风险增加， 加速动脉粥样硬化已知的风险因素（吸烟、肥胖、家庭 CAD、胆固醇升高、糖尿病、高血压、同型半胱氨酸 久坐不动的生活方式很重要，但这种疾病或其治疗似乎 是最重要的然而，在实践中， 最重要的是，没有证据表明治疗这些疾病 更积极的因素会在结果之后。 我们建议进行一项可行性研究，以确定招聘率和成本， 积极危险因素管理与普通危险因素管理的随机试验 一级和二级预防管理加速 系统性红斑狼疮的动脉粥样硬化大型随机对照 一项积极的动脉粥样硬化血管疾病改善策略的试验， 旨在使用B复合维生素进行一级预防，普伐他汀是一种新的 系统性红斑狼疮妇女电话危险因素管理系统

DESCRIPTION (Taken from the application): Systemic Lupus Erythematosus (SLE) affects over 200,000 Americans. It has been known for over 20 years that patients with SLE are at increased risk for accelerated atherosclerosis. Known risk factors (smoking, obesity, family history of CAD, elevated cholesterol, diabetes, hypertension, homocysteine, sedentary life style are important but the disease or its treatment appears to be the most important of all. Risk factor modification in practice, however, is far from ideal and, most importantly there is no evidence that treating these factors more aggressively would after outcome. We propose a feasibility study to determine recruitment rate and costs of a randomized trial of aggressive risk factor management versus usual risk factor management in the primary and secondary prevention of accelerated atherosclerosis of system lupus erythematosus. The large randomized controlled trial of an aggressive atherosclerosis vascular disease modifying strategy is aimed at primary prevention using B complex vitamins, Pravastatin, an a novel telephone risk factor management system in women with SLE.